Date: 2012-07-09
Type of information: R&D agreement
Compound: novel signaling pathways and drug targets in oncology, cardiometabolic, fibrotic and infectious diseases
Company: Boehringer Ingelheim (Germany) Harvard’s Office of Technology Development (USA)
Therapeutic area: Cancer - Oncology - Cardiovascular diseases - Metabolic diseases - Infectious diseases
Type agreement: R&D
collaboration
Action mechanism:
Disease: oncology, cardiometabolic, fibrotic and infectious diseases.
Details: Boehringer Ingelheim has established a translational research collaboration with the Presidents and Fellows of Harvard College. The goal of the collaboration is for the scientists of Boehringer Ingelheim to work together with the scientific community of Harvard to advance our knowledge in areas of high unmet medical need. The focus of the different research projects is to identify and investigate novel signaling pathways and drug targets in oncology, cardiometabolic, fibrotic and infectious diseases.
Under an agreement negotiated between Boehringer Ingelheim and Harvard’s Office of Technology Development, the collaboration will sponsor a variety of research projects by awarding funds to support proposals selected by a joint research committee comprised of representatives from the Harvard Medical School ICCB-Longwood Screening Facility, various Harvard Affiliated Institutions and Boehringer Ingelheim. The funding will enable the Harvard research community to address several RNAi screening projects using specifically tailored screening systems. To date, the collaboration has selected and supported eight projects of scientific and educational value in the areas of cancer stem cell survival, replication of detrimental viruses and fibrotic processes.
Financial terms:
Latest news:
